Special Issue

Inflammation and Cancer: Origins, Mechanisms and Consequences

Message from the Guest Editor

Tumorigenesis is a complex mechanism based on the sum of multiple factors that lead to the consolidation and propagation of cancer cells. It is now wellestablished that, in addition to the triggering events that promote the genetic alteration, the interaction with the host immune system (and, more broadly, with the surrounding microenvironment) has a crucial role in the development of different types of cancers. The aim of this Special Issue aims to highlight the connection between the host microenvironment and the tumorigenic process, with a special focus on inflammatory pathways. This will include original articles and literature reviews that provide new insight into the fundamental bond between inflammation and carcinogenesis, paving the way to novel prognostic factors as well as adjuvant therapies for the prevention and treatment of cancer pathologies. Keywords

- inflammation
- tumorigenesis
- tumor microenvironment
- cytokines and chemokines
- adipokines

Guest Editor

Dr. Bianca Vezzani

Department of Medical Sciences, Section of Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy

Deadline for manuscript submissions

closed (30 September 2023)



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/145948

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).